**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**



CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
  SECURITIES EXCHANGE ACT OF 1934

Date of report: January 3, 2005
  Date of earliest event reported: December 31, 2004

**PFIZER INC.**
  (Exact name of registrant as specified in its charter)

|**Delaware**                                                                                       | **1-3619**               | **13-5315170**                      
|-------------------------------------------------------------------------------------------------- | ------------------------ | ------------------------------------
|(State or other Jurisdiction of incorporation)                                                     | (Commission File Number) | (I.R.S. Employer Identification No.)
|**235 East 42nd Street 
          New York, New York**(Address of principal executive offices)**** |                          | **10017**
        (Zip Code)        

> Registrant's telephone number, including area code:(212) 573-2323

Check the appropriate box below if the Form 8-K filing is intended
  to simultaneously satisfy the obligation of the registrant under any of the
  following provisions:

[ ] Written communication pursuant to Rule 425 under the Securities Act (17
  CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
  CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
  Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
  Act (17 CFR 240.13e-4(c))



|Item 8.01 | Other Events
|--------- | ------------

On December 31, 2004, Pfizer Inc. issued a press release announcing that it
  has received approval from the U.S. Food and Drug Administration to market LyricaTM
  (pregabalin capsules) for the management of neuropathic pain associated with
  diabetic peripheral neuropathy and postherpetic neuralgia. A copy of the press
  release is included as Exhibit 99 to this report and is incorporated herein
  by reference.

|Item 9.01 Financial Statements and Exhibits |  | 
|------------------------------------------- |  | 

|(c) Exhibits |                                                       | 
|------------ | ----------------------------------------------------- | 
|Exhibit 99   | Press Release of Pfizer Inc. dated December 31, 2004. | 



**SIGNATURE**

Under the requirements of the Securities Exchange Act of 1934, the registrant
  has caused this report to be signed on its behalf by the authorized undersigned.

|                       |  | PFIZER INC.                                                     
|---------------------- |  | ----------------------------------------------------------------
|                       |  |                                                                 
|                       |  | By: /s/ Margaret M. Foran
        Margaret M. Foran             
|                       |  | Title: Vice President-Corporate
        Governance and Secretary
|Dated: January 3, 2005 |  |                                                                 

> 

EXHIBIT INDEX

|Exhibit No. | Description                                          
|----------- | -----------------------------------------------------
|            |                                                      
|99          | Press Release of Pfizer Inc. dated December 31, 2004.